Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | September 30, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.44 · Expires 2036-09-30 | Direct | 380 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 380 · Balance 380 F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 21:57 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 380 | $8.68 Strike: $10.44 | $3,296.88 |
DisclosureSEC source: 0001193125-26-412658 · ownership.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 380 shares Expires 2036-09-30 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:20 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 381 | $8.64 Strike: $10.30 | $3,291.46 |
DisclosureSEC source: 0001979825-26-000006 · ownership.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 381 Underlying: Common Stock · 381 shares Expires 2036-06-30 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:34 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001979825-26-000004 · ownership.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:08 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 779 | $4.11 Strike: $4.90 | $3,204.81 |
DisclosureSEC source: 0001979825-26-000002 · ownership.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 779 shares Expires 2036-03-31 F1 · derivative.exercise_date: This award has been granted in lieu of normal quarterly cash payments. The underlying award quantity is fully vested at time of grant. Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 12:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantCommon Stock | 2,141 | $4.67 | $9,998.47 |
DisclosureSEC source: 0000950170-25-090195 · ownership.xml · nonDerivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,141 F1 · kind: Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 12:36 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000950170-25-087703 · ownership.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 12:36 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0000950170-24-078170 · ownership.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 12:45 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 28,480 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001209191-23-035623 · doc4.xml · derivative · entry 1 Loggia Nicoletta · CIK 0001979825 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,480 Underlying: Common Stock · 28,480 shares Expires 2033-06-07 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.